Market Trends of France Blood Glucose Monitoring Industry
Increasing Type-1 diabetes population across France
Over the forecast period 2022-2027, the population of people with type 1 diabetes in France increased at a rate greater than 3%. France is one of 59 countries in the IDF EUR zone. Furthermore, diabetes will affect 61 million people in Europe and 537 million worldwide in 2021, rising to 69 million by 2045. According to an EU Commission survey, the number of people with chronic diabetes is highest in France, with one in every ten suffering from the disease. Diabetes is common in France, even though the rules' target of 80% compliance with recommended healthcare consultations is not always met. New techniques that focus on the patient and the environment are being developed to encourage proactive therapy adjustment and reduce therapeutic inertia. Physician education and information are necessary to lessen the burden of complications and hospitalizations associated with diabetes. Therefore, owing to the factors above, the growth of the studied market is anticipated in France Country. Diabetes has the highest prevalence among all chronic conditions, covered 100% by France's statutory health insurance (SHI), and the number of covered patients has doubled in the past 10 years. France is one of the major countries in the Europe region. According to the World Health Organization (WHO), about a million are diagnosed with diabetes in France. The prevalence of diabetes is growing among all ages in France, which can be attributed to the growing obese population, unhealthy diets, and sedentary lifestyles.
Furthermore, approximately 0.26 million are estimated to live with Type 1 diabetes in the region. Thus, the rising prevalence of diabetes and obesity, growing awareness regarding diabetic care, healthcare expenditure, and technological advancements are a few factors that are further driving the market for diabetes care devices in France. France has a centralized healthcare system where all reimbursement decisions are taken nationally and applied to all countries. For diabetes technological devices in France, the reimbursement is based on the tariff system.
Continuous Glucose Monitoring Holds Highest CAGR in France Blood Glucose Monitoring Market.
In France, the G6 RT-CGM system is likely more cost-effective than SMBG over a lifetime horizon for individuals with long-standing T1D. One of the commitments made in the French National Health Strategy for 2018-2022 is to ensure immediate and universal access to innovations such as new medical devices. However, due to rising financial pressures in many healthcare systems, the cost of innovative technologies must be justified by a clinical benefit sufficient to outperform currently available technologies in light of the Dexcom G6 RT-CGM system's incremental clinical and QoL benefits in France. Because people with diabetes are more likely to contract COVID-19, French companies are ensuring an adequate supply of required Monitoring Devices in the market to ensure the well-being of the affected citizens.
CGMs are used to deliver a further descriptive picture of blood glucose patterns and trends than what can be achieved by traditional routine checking of glucose levels at set intervals. The current CGM devices can either retrospectively display the trends in blood glucose levels by downloading the data or give a real-time picture of glucose levels through receiver displays. Most real-time CGMs can alert patients, parents, or caregivers during actual or pending glycemic visits to facilitate the timely management of blood glucose. This factor, along with the fact that CGM devices are becoming cheaper with the advent of new technologies, like cell phone integration, the CGM market is expected to witness steady growth during the forecast period.
The rise in national awareness of diabetes is anticipated to drive the adoption of both SMBGs and CGMs on account of the prognostic and diagnostic treatment of diabetes.
